Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Review, H1 2016', provides in depth analysis on Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted pipeline therapeutics. 

The report provides comprehensive information on the Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30)
- The report reviews Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) Overview 8
Therapeutics Development 9
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Stage of Development 9
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Therapy Area 10
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Indication 11
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Companies 14
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Universities/Institutes 16
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Companies Involved in Therapeutics Development 22
Asana BioSciences, LLC 22
Endo Pharmaceuticals Inc. 23
Johnson & Johnson 24
Leon-Nanodrugs GmbH 25
Millennium Pharmaceuticals, Inc. 26
Novartis AG 27
Orion Oyj 28
Tokai Pharmaceuticals, Inc. 29
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Drug Profiles 30
abiraterone acetate - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
abiraterone acetate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ASN-001 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CFG-920 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
EN-3356 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
galeterone - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ketoconazole - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ODM-204 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
orteronel - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
seviteronel - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecules to Inhibit CYP17 and CYP11B2 for Prostate Cancer - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Inhibit CYP17 Lyase - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Dormant Projects 55
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Discontinued Products 56
Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Featured News & Press Releases 57
May 18, 2016: Janssen to Present Data on Abiraterone acetate at the 2016 American Society of Clinical Oncology Annual Meeting 57
May 18, 2016: Tokai Announces Publication of Three Abstracts on Galeterone at the 2016 ASCO Annual Meeting 58
May 12, 2016: Innocrin Pharmaceuticals Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer 59
Apr 26, 2016: Tokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting 60
Mar 30, 2016: Tokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients 60
Mar 21, 2016: NICE recommends abiraterone for prostate cancer 61
Mar 14, 2016: Greater Survival Benefit Shown in Men with Early and Less Aggressive Metastatic Castration-Resistant Prostate Cancer Treated with ZYTIGA Plus Prednisone 62
Jan 08, 2016: Tokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium 64
Jan 07, 2016: Tokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program 64
Jan 06, 2016: Innocrin Pharmaceuticals Granted Fast Track Designation by FDA for VT-464 Treatment of Patients with Metastatic Castrate-resistant Prostate Cancer 65
Dec 11, 2015: NICE publishes draft guidance on Abiraterone prostate cancer treatment 66
Dec 03, 2015: Study shows abiraterone acetate is useful even in most aggressive prostate cancers 67
Nov 07, 2015: Tokai Announces Presentation of Galeterone Data in Models of the AR-V7 Splice Variant at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 68
Nov 04, 2015: Blood test picks out prostate cancer drug resistance 68
Oct 08, 2015: Tokai Pharmaceuticals Announces Presentation of AR-V7 Clinical Trial Assay at the Prostate Cancer Foundation's Annual Scientific Retreat 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables

Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Assessment by Monotherapy/Combination Products, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Asana BioSciences, LLC, H1 2016 22
Pipeline by Endo Pharmaceuticals Inc., H1 2016 23
Pipeline by Johnson & Johnson, H1 2016 24
Pipeline by Leon-Nanodrugs GmbH, H1 2016 25
Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 26
Pipeline by Novartis AG, H1 2016 27
Pipeline by Orion Oyj, H1 2016 28
Pipeline by Tokai Pharmaceuticals, Inc., H1 2016 29
Dormant Projects, H1 2016 55
Discontinued Products, H1 2016 56